Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes

ABSTRACT: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE140082 | GEO | 2019/11/08

REPOSITORIES: GEO